: iStockAnalyst.com Symbols Feed

Federal Circuit Affirms Dismissal of Declaratory Judgment Counterclaims in Trusopt/Cosopt Case

Fri, 10 Oct 2008 14:40:00 GMT

Merck & Co. v. Apotex, No. 2008-1133 (Fed. Cir. 2008) In 2005, Hi-Tech Pharmacal became the first company to file a paragraph IV certification relating to Merck's glaucoma drugs Trusopt and Cosopt. Hi-Tech filed paragraph IV certifications with respect to all three of the Orange Book-listed patents for these drugs: U.S. Patent Nos. 4,797,413; 6,248,735; and [More...]

Federal Circuit Affirms Dismissal of Prasco's Declaratory Judgment Suit Against Medicis

Tue, 07 Oct 2008 16:47:00 GMT

Prasco v. Medicis Pharm. Corp., No. 2007-1524 (Fed. Cir. 2008) Medicis markets a benzoyl peroxide cleansing product, Triaz. Prasco sells a competing benzoyl peroxide cleansing product, Oscion. Prasco filed a declaratory judgment complaint, requesting judgment that Oscion does not infringe four patents owned or licensed by Medicis. Prasco alleged declaratory judgment jurisdiction based on three facts: (1) Medicis marked its Triaz products with the numbers of the four patents-in-suit; (2) Medicis previously sued Prasco for infringement of an unrelated patent by a different cleanser product; and (3) Medicis refused to provide Prasco with a covenant not to sue on the four patents-in-suit. In an opinion released August 15th, the Federal Circuit affirmed the district court's[More...]

Another Seal of Approval For Micromet

Tue, 19 Aug 2008 14:47:00 GMT

Normal 0[More...]

American On Sale

Fri, 25 Jul 2008 15:45:00 GMT

As highlighted in BusinessWeek, and illustrated by the recent acquisition of Anheuser-Busch by InBev, the United States is on sale. The weak stock market and even weaker U.S. dollar are allowing foreign buyers to purchase U.S. companies at discount prices[More...]

Periodicals Wrap-Up for Friday, May 23rd

Fri, 23 May 2008 13:22:46 GMT

WALL STREET JOURNAL: In what may trump a GBP1.6B bid from a private-equity led consortium consisting of of Goldman Sachs Capital Partners (GS), Candover Partners (CDRIF), and Alpinvest, Expro International Group (EXPRF) said it received a GBP1.71B bid[More...]

Analyst Comments: Stoneridge, Array Pharma, Finisar, Infinity Pharma, CombinatoRx, Ness Tech, Human Genome

Tue, 06 May 2008 20:48:54 GMT

Stoneridge, Inc. (SRI) is aggressively cutting costs and benefiting from the growth of the commercial vehicle market. Increased use of electronics in vehicles is also benefiting the company. However, a squeeze between raw materials and prices, along with weak vehicle demand, force us to rate the shares a Hold with a target price of $15.50, which is 19.6x our 2008 estimate. Stoneridge reported first quarter...[More...]

District Court Dismisses Impax's Declaratory Judgment Complaint in ANDA Case Against Medicis

Fri, 25 Apr 2008 05:01:26 GMT

Impax Labs. v. Medicis Pharm., No. C-08-0253 MMC (N.D. Cal. 2008)[More...]

AstraZeneca is Waiting to be Found by Investors

Sat, 22 Mar 2008 20:42:56 GMT

AstraZeneca plc (ADR) (Public, NYSE:AZN) the U.K.'s second-largest drugmaker is just $2 away from their 52-week low yet they have 10 drugs in Phase 3 Trials and their lineup of 12 drugs rake in more than $1 billion a year in revenue. So what's the deal?[More...]

Big Pharma?s Expected Revenues

Thu, 12 Jul 2007 01:06:07 GMT

Ahead of second quarter earnings results, we sat down with Zacks senior drug industry analyst Jason Napodano, CFA to find out what he expects from this group in the weeks to come. What are your general expectations ahead of second quarter earnings? I think the second quarter for pharma is going to be good - not great. Better than things have been in the past, but nothing stellar. When we're talking about large pharma, we're talking about the U.S. pharmaceutical companies: the Mercks (MRK), the Pfizers (PFE), the Bristols (BMY), the Johnson Johnsons [JJ] (JNJ); I also include the Europea[More...]

Amman Stock Exchange: Weekly Analysis

Sun, 20 Sep 2009 16:48:00 GMT

Sep. 20--AMMAN -- Amman bourse posted gains for the fourth consecutive week driven by rising share prices of strategic companies in the real estate and financial services sectors.
Amid relatively high trading volumes, the index of Amman Stock Exchange (ASE) closed last week at 2,647.75 points, a slight increase of 0.23 per cent over the closing level of the previous week.
Except for the industrial and services sectors which declined by 1.5 per cent and 0.5 per cent respectively, all other indices advanced led by the diversified financial services which went up by 2.9 per cent.

[More...]

Amman Stock Exchange

Sun, 06 Sep 2009 16:47:00 GMT

Sep. 6--WEEKLY ANALYSIS
AMMAN -- Amid notably higher trading volumes, the general index of Amman Stock Exchange (ASE) crossed the 2,600 point barrier on Thursday and closed last week at 2,604.98 points, 4.1 per cent higher than the closing level at the end of the previous week.
The index gained in each of last week's trading sessions driven by improved sentiment in the market following the Cabinet's decision to grant the Jordan Petroleum Refinery an exclusive 15-year concession to execute its fourth expansion project.

[More...]

Amman Stock Exchange: Weekly Analysis

Sun, 23 Aug 2009 15:45:00 GMT

Aug. 23--AMMAN -- Amid substantially lower trading volumes, the Amman bourse continued to shed more points for the third week in a row driven by declining share prices of most strategic companies.
The general index of the Amman Stock Exchange (ASE) ended Wednesday's trading session at 2,454.48 points to record its lowest level since November 4, 2004, only to rise slightly on Thursday and close last week at 2,462.53 points, a drop of 2.8 per cent compared to the closing level in the previous week.
The most actively traded shares last week were those of Taameer Jordan, Contemporary for Housing Projects, and Office Holding Group with a combined value traded of JD14.8 million representing 18.2 per cent of the week's total value traded.

[More...]

MedImmune Licensing New Antibody-Enhancing Technologies to Further Strengthen its Development-Stage Pipeline

Thu, 08 Dec 2005 13:25:00 GMT

MedImmune, Inc. announced today that it continues to build upon its corporate initiatives to expand and expedite the development of its product pipeline by licensing rights to antibody-enhancing technologies. The latest technology agreements MedImmune has entered into are with BioWa, Inc. and Xencor, Inc. from which MedImmune has gained access to two different technologies that may enhance the effectiveness of monoclonal antibodies targeting cancer.[More...]